Blocking the Monocyte Chemoattractant Protein-1/CCR2 Chemokine Pathway Induces Permanent Survival of Islet Allografts through a Programmed Death-1 Ligand-1-Dependent Mechanism

Journal of Immunology

Volumn 171, Issue 12, 2003, Pages 6929-6935

  Lee, Iris ^a   Wang, Liqing ^a   Wells, Andrew D ^a   Ye, Qunrui ^a   Han, Rongxiang ^a   Dorf, Martin E ^b   Kuziel, William A ^c   Rollins, Barrett J ^d   Chen, Lieping ^e   Hancock, Wayne W ^a,f  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MAYO GRADUATE SCHOOL   (United States)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; LIGAND; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; MONOCYTE CHEMOATTRACTANT PROTEIN 1 RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PD 1 PROTEIN; PD L1 PROTEIN; PD-1 PROTEIN; PD-L1 PROTEIN; PEPTIDE; PLASMA PROTEIN; PROGRAMMED CELL DEATH PROTEINS 1; PROGRAMMED DEATH 1 PROTEIN; PROTEIN; PROTEIN B7 H1; PROTEIN PD L1; RAPAMYCIN; RECEPTOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL CLONE; CELL DIFFERENTIATION; CELL DIVISION; CELL MIGRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; FEMALE; GENETICS; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLISM; METHODOLOGY; MONONUCLEAR CELL; MOUSE; MOUSE MUTANT; MOUSE STRAIN; NONHUMAN; ORGAN CULTURE; PANCREAS ISLET TRANSPLANTATION; PATHOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TISSUE INJURY; TRANSPLANTATION; UPREGULATION;

EID: 10744225261     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.12.6929     Document Type: Article

References (48)

1. Murphy, P. M., M. Baggiolini, I. F. Charo, C. A. Hebert, R. Horuk, K. Matsushima, L. H. Miller, J. J. Oppenheim, and C. A. Power. 2000. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 52:145.
2. Luther, S. A., and J. G. Cyster. 2001. Chemokines as regulators of T cell differentiation. Nat. Immunol. 2:102.
3. Sallusto, F., C. R. Mackay, and A. Lanzavecchia. 2000. The role of chemokine receptors in primary, effector, and memory immune responses. Annu. Rev. Immunol. 18:593.
4. Hancock, W. W., W. Gao, K. L. Faia, and V. Csizmadia. 2000. Chemokines and their receptors in allograft rejection. Curr. Opin. Immunol, 12:511.
5. Hancock, W. W., L. Wang, Q. Ye, R. Han, and I. Lee. 2003. Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Curr. Opin. Immunol. 15:479.
6. Hancock, W. W., B. Lu, W. Gao, V. Csizmadia, K. Faia, J. A. King, S. T. Smiley, M. Ling, N. P. Gerard, and C. Gerard. 2000. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J. Exp. Med. 192:1515.
7. Hancock, W. W., W. Gao, V. Csizmadia, K. L. Faia, N. Shemmeri, and A. D. Luster. 2001. Donor-derived IP-10 initiates development of acute allograft rejection. J. Exp. Med. 193:975.
8. Gao. W., K. L. Faia. V. Csizmadia, S. T. Smiley, D. Soler, J. A. King, T. M. Danoff, and W. W. Hancock. 2001. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 72:1199.
9. Gao, W., P. S. Topham, J. A. King, S. T. Smiley, V. Csizmadia. B. Lu, C. J. Gerard, and W. W. Hancock. 2000. Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. J. Clin. Invest. 105:35.
10. Haskell, C. A., W. W. Hancock, D. J. Salant, W. Gao, V. Csizmadia, W. Peters, K. Faia, O. Fituri, J. B. Rottman, and I. F. Charo. 2001. Targeted deletion of CX3CRI reveals a role for fractalkine in cardiac allograft rejection. J. Clin. Invest. 108:679.
11. Abdi, R., R. N. Smith, L. Makhlouf, N. Najafian, A. D. Luster. H. Auchincloss, and M. H. Sayegh. 2002. The role of CC chemokine receptor 5 (CCR5) in islet allograft rejection. Diabetes 51:2489.
12. Piemonti, L., B. E. Leone, R. Nano, A. Saccani, P. Monti, P. Maffi, G. Bianchi, A. Sica, G. Peri, R. Melzi, et al. 2002. Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation. Diabetes 51:55.
13. Chen, M. C., P. Proost, C. Gysemans, C. Mathieu, and D. L. Eizirik. 2001. Monocyte chemoattractant protein-1 is expressed in pancreatic islets from prediabetic NOD mice and in interleukin-1β-exposed human and rat islet cells. Diabetologia 44:325.
14. Fuentes, M. E., S. K. Durham, M. R. Swerdel, A. C. Lewin, D. S. Barton, J. R. Megill, R. Bravo, and S. A. Lira. 1995. Controlled recruitment of monocytes and macrophages to specific organs through transgenic expression of monocyte chemoattractant protein-1. J. Immunol. 155:5769.
15. Gunn, M. D., N. A. Nelken, X. Liao. and L. T. Williams. 1997. Monocyte chemoattractant protein-1 is sufficient for the chemotaxis of monocytes and lymphocytes in transgenic mice but requires an additional stimulus for inflammatory activafion. J. Immunol. 158:376.
16. Lu, B., B. J. Rutledge, L. Gu, J. Fiorillo, N. W. Lukacs, S. L. Kunkel, R. North, C. Gerard, and B. J. Rollins. 1998. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J. Exp. Med. 187:601.
17. Furutani, Y., H. Nomura, M. Notake, Y. Oyamada, T. Fukui, M. Yamada, C. G. Larsen, J. J. Oppenheim, and K. Matsushima. 1989. Cloning and sequencing of the cDNA for human monocyte chemotactic and activating factor (MCAF). Biochem. Biophys. Res. Commun. 159:249.
18. Carr, M. W., S. J. Roth, E. Luther, S. S. Rose, and T. A. Springer. 1994. Monocyte chemoattractant protein I acts as a T-lymphocyte chemoattractant. Proc. Natl. Acad. Sci. USA 91:3652.
19. Gu, L., S. Tseng, R. M. Horner, C. Tam, M. Loda, and B. J. Rollins. 2000. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 404:407.
20. Charo, I. F., S. J. Myers, A. Herman, C. Franci, A. J. Connolly, and S. R. Coughlin. 1994. Molecular cloning and functional expression of two monocyte chemoattractant protein I receptors reveals alternative splicing of the carboxyl-terminal tails. Proc. Natl. Acad. Sci. USA 91:2752.
21. Traynor, T. R., W, A. Kuziel, G. B. Toews, and G. B. Huffnagle, 2000. CCR2 expression determines TI versus T2 polarization during pulmonary Cryptococcus neoformans infection. J. Immunol. 164:2021.
22. Traynor, T. R., A. C. Herring, M. E. Dorf, W. A. Kuziel, G. B. Toews, and G. B. Huffnagle. 2002. Differential roles of CC chemokine ligand 2/monocyte chemotactic protein-1 and CCR2 in the development of TI immunity. J. Immunol. 168:4659.
23. Kurihara, T., G. Warr, J. Loy, and R. Bravo. 1997. Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J. Exp. Med. 186:1757.
24. Boring, L., J. Gosling, S. W. Chensue, S. L. Kunkel, R. V. Farese, Jr., H. E. Broxmeyer, and I. F. Charo. 1997. Impaired monocyte migration and reduced type I (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J. Clin. Invest. 100:2552.
25. Fife, B. T., G. B. Huffnagle, W. A. Kuziel, and W. J. Karpus. 2000. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J. Exp. Med. 192:899.
26. Izikson, L., R. S. Klein, I. F. Charo, H. L. Weiner, and A. D. Luster. 2000. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor CCR2. J. Exp. Med. 192:1075.
27. Kuziel, W. A., S. J. Morgan, T. C. Dawson, S. Griffin, O. Smithies, K. Ley, and N. Maeda. 1997. Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc. Natl. Acad. Sci. USA 94:12053.
28. Luo, Y., J. Laning, M. Hayashi, P. R. Hancock, B. Rollins, and M. E. Dorf. 1994. Serologic analysis of the mouse beta chemokine JE/monocyte chemoattractant protein-1. J. Immunol. 153:3708.
29. Dong, H., S. E. Strome, D. R. Salomao, H. Tamura. F. Hirano, D. B. Flies, P. C. Roche, J. Lu, G. Zhu, K. Tamada, et al. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8:793.
30. Mack, M., J. Cihak, C. Simonis, B. Luckow, A. E. Proudfoot, J. Plachy, H. Bruhl, M. Frink, H. J. Anders, V. Vielhauer, et al. 2001. Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J. Immunol. 166:4697.
31. Yang, H., D. Thomas, D. J. Boffa, R. Ding, B. Li, T. Muthukumar, V. K. Sharma, M. Lagman, G. X. Luo, S. Kapur, et al. 2002. Enforced c-REL deficiency prolongs survival of islet allografts. Transplantation 74:291.
32. Ozkaynak, E., L. Wang, A. Goodearl, K. McDonald, S. Qin, T. O'Keefe, T. Duong, T. Smith, J. C. Gutierrez-Ramos, J. B. Rottman, et al. 2002. Programmed death-1 targeting can promote allograft survival. J. Immunol. 169:6546.
33. Suchin, E. J., P. B. Langmuir, E. Palmer, M. H. Sayegh, A. D. Wells, and L. A. Turka. 2001. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J. Immunol. 166:973.
34. Ishida, Y., Y. Agata, K. Shibahara, and T. Honjo. 1992. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11:3887.
35. Dong, H., G. Zhu, K. Tamada, and L. Chen. 1999. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5:1365.
36. Freeman, G. J., A. J. Long, Y. Iwai, K. Bourque, T. Chemova, H. Nishimura, L. J. Fitz, N. Malenkovich, T. Okazaki, M. C. Byme, et al. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192:1027.
37. Latchman, Y., C. R. Wood, T. Chernova, D. Chaudhary, M. Borde, I. Chemova, Y. Iwai, A. J. Long, J. A. Brown, R. Nunes, et al. 2001. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2:261.
38. Tseng, S. Y., M. Otsuji, K. Gorski, X. Huang, J. E. Slansky, S. I. Pai, A. Shalabi, T. Shin, D. M. Pardoll, and H. Tsuchiya. 2001. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J. Exp. Med. 193:839.
39. Grewal, I. S., B. J. Rutledge, J. A. Fiorillo, L. Gu, R. P. Gladue, R. A. Flavell, and B. J. Rollins, 1997. Transgenic monocyte chemoattractant protein-1 (MCP-1) in pancreatic islets produces monocyte-rich insulitis without diabetes: abrogation by a second transgene expressing systemic MCP-1. J. Immunol. 159:401.
40. Iwai, Y., S. Terawaki, M. Ikegawa, T. Okazaki, and T. Honjo. 2003. PD-1 inhibits antiviral immunity at the effector phase in the liver. J. Exp. Med. 198:39.
41. Ansari, M. J., A. D. Salama, T. Chitnis, R. N. Smith, H. Yagita, H. Akiba, T. Yamazaki, M. Azuma, H. Iwai, S. J. Khoury, et al. 2003. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J. Exp. Med. 198:63.
42. Salama. A. D., T. Chitnis, J. Imitola, H. Akiba. F. Tushima, M. Azuma, H. Yagita, M. H. Sayegh, and S. J. Khoury. 2003. Critical role of the programmed death-I (PD-1) pathway in regulation of experimental autoimmune encephalo-myelitis. J. Exp. Med. 198:71.
43. Ishida, M., Y. Iwai, Y. Tanaka, T. Okazaki, G. J. Freeman, N. Minato, and T. Honjo. 2002. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol. Lett. 84:57.
44. Yamazaki, T., H. Akiba, H. Iwai, H. Matsuda, M. Aoki, Y. Tanno, T. Shin, H. Tsuchiya, D. M. Pardoll, K. Okumura, et al. 2002. Expression of programmed death I ligands by murine T cells and APC. J. Immunol. 169:5538.
45. Loke, P., and J. P. Allison. 2003. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc. Natl. Acad. Sci. USA 100:5336.
46. Mazanet, M. M., and C. C. Hughes. 2002. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J. Immunol. 169:3581.
47. Eppihimer, M. J., J. Gunn, G. J. Freeman, E., A. Greenfield, T. Chernova, J. Erickson, and J. P. Leonard. 2002. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation 9:133.
48. Brown, J. A., D. M. Dorfman, F. R. Ma, E. L. Sullivan, O. Munoz, C. R. Wood, E. A., Greenfield, and G. J. Freeman. 2003. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170:1257.